Learn more about INPLASYⓇ
Our Mission
"To give everyone the opportunity to register and share systematic review protocols almost instantly, without barriers. INPLASY help reduces duplication efforts of reviews, help minimize reporting bias, and increase research transparency."
Our Vision
"Delivering innovative international platform to register systematic review protocols."
Our History
INPLASY is an international platform of registered systematic review and meta-analysis protocols officially launched in March 2020. Protocols registration in INPLASY increased rapidly in the first 12 months, reaching more than 1,400 records of authors from 25 countries. On 1 February 2024, INPLASY had more than 7,5k users registered on the website, and more than 500,000 views from 181 countries, reaching more than 5.8K records of authors from 75 countries.
Protocols from 75 countries (Angola, Australia, Austria, Bangladesh, Belgium, Bolivia, Brazil, Bulgaria, Burkina Faso, Canada, Chile, China, Colombia, Croatia, Denmark, Ecuador, Egypt, Ethiopia, Finland, France, Gambia, Germany, Greece, Hungary, India, Indonesia, Iran, Ireland, Israel, Italy, Japan, Jordan, Kenia, Lebanon, Lithuania, Malaysia, Mexico, Morocco, Mozambique, New Zealand, Nigeria, Norway, Oman, Pakistan, Peru, Poland, Portugal, Republic Czechia, Republic of Korea, Romania, Russia, Saudi Arabia, Senegal, Serbia, Singapore, Slovenia, South Africa, Spain, Siri Lanka, Sweden, Switzerland, Senegal, Taiwan, Tanzania, Thailand, The Netherlands, Tunisia, Turkey, Uganda, United Kingdom, United Arab Emirates, United States of America, Vietnam and Yemen)
More than 500K website views from 176 countries
Updated on 1 February 2024
1 – The international platform of registered systematic review and meta-analysis protocols (INPLASY) at 3 years: an analysis of 4,658 registered protocols on inplasy.com, platform features, and website statistics. Canellas et al. Front. Res. Metr. Anal., 31 July 2023 https://doi.org/10.3389/frma.2023.1135853
It is essential to identify evidence syntheses that already exist and ongoing systematic reviews before starting a new project to avoid duplication effort. Although registration in PROSPERO is considered the standard, it is not possible for a single platform to be able to register all systematic review protocols developed around the world. Solla et al. showed that even PROSPERO registration does not prevent double review registration on the same topic. Thus, the authors are responsible for searching for ongoing systematic reviews in the pipeline before submitting their protocols.
2 – Solla F, Bertoncelli CM, Rampal V. Does the PROSPERO registration prevent double review on the same topic? BMJ Evid Based Med. 2020 Feb 13:bmjebm-2020-111361. doi: 10.1136/bmjebm-2020-111361. PMID: 32054725.
The COVID-END resources and tools for researchers considering and conducting COVID-19 evidence syntheses were last updated by McMaster University on 17 June 2020. Before starting a new project, this working group indicates that researchers should seek ongoing reviews not only in PROSPERO, but in INPLASY, National Collaborating Centre, Centre for Evidence Based Medicine, and VA Evidence Synthesis Program.
3 – COVID-END – COVID-19 Evidence Network to support Decision-making – Resources for researchers – Identify ongoing reviews/ avoid duplication effort; 2.2.2 (Available: https://www.mcmasterforum.org/docs/default-source/covidend/covid-end_researchers.pdf?sfvrsn=437e56d5_4).
Our Values
INPLASY facilitates increased transparency in the review process once all protocols are published within 48 hours after the submission. The method is based on a basic check, without any delay, increasing the potential to reduce research waste and duplication efforts.
